Table I.

Age, immunological, and virological characteristics and treatment of patients

Subject ID No.Pattern of DominancecDominant Vβ Family(s)HIV RNA Copies/ml (log10)Age (yr)CDC ClassCD4 %CD8 %ARTa
Group 1
964Major4, 1, 12, 22<200 (<2.3)1.1N13132Yes
860Major1, 2, 3, 5.2, 7, 22, 11, 1543,575 (4.6)1.6C13445Yes
677Major5.1, 15, 99,408 (3.9)4B14035Yes
121Major19, 5.1, 5.2, 11, 12, 89,068 (3.9)5C12542Yes
117bMajor23, 2, 14, 24, 16, 958,812 (4.9)7N14333No
569Major2, 14, 21, 15648,678 (5.8)8.4B3358Yes
804bMajor2, 5.1, 7, 17, 1420,160 (4.3)9N13037No
113Major24, 3, 13.1, 16, 201,486 (3.1)11B12644Yes
129Major6, 7, 174,574 (3.6)13A13746Yes
988Major18, 3, 19, 14394,156 (5.6)13.5A31023Yes
1075Minor2, 5.21,039 (3.0)0.75N13022Yes
114Minor6, 2276,509 (4.8)5.4C13042No
Group 2
992Single189,639 (4.9)7.5B3967Yes
658Single1850,099 (4.6)8.3B3247Yes
109Single767,037 (4.8)9.4B3734Yes
1028None25,571 (4.4)5.4B3728Yes
124None131,924 (5.1)6.0B31756Yes
108None53,772 (4.7)9.6B3965Yes
029None21,888 (4.3)10.4B31221Yes
675None2,022 (3.4)12.6B31448Yes
780None531,429 (5.7)14A3750Yes
962None94,356 (4.9)15C3259Yes
  • a ART with dual or triple drug combinations including AZT, 3TC, ddI, d4T, Nevirapine, and the protease inhibitors Nelfinavir, Ritonavir, and Saquinavir.

  • b Patients identified as LTNPs.

  • c Major = three or more Vβ families involved, minor = two Vβ families, single = one Vβ family, none = no clonal dominance.